Dublin, Ireland, 25 January 2021 - Ovoca Bio plc (LSE: OVB; ISE: OVXA), a biopharmaceutical company with a focus on women s health, announces that an Extraordinary General Meeting of the Company will be held at 17 Pembroke Street Upper, Dublin 2, Ireland on 16 February 2021 at 11.00 am (the EGM ). The EGM is being convened to seek the approval of shareholders to certain resolutions which are intended to facilitate the migration of the Company s ordinary shares from the CREST System to the central securities depository ( CSD ) system operated by Euroclear Bank SA/NV, an international CSD incorporated in Belgium, following the withdrawal of the UK from the EU, and to make subsequent changes to the Company s Articles of Association (the Resolutions ).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
Amryt Pharma plcJanuary 20, 2021 GMT
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce that the National Institute for Health and Care Excellence (“NICE”) has approved Myalepta® (metreleptin) for reimbursement in England and Wales as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy (GL) in adults and children two years of age and above and fa
Oxford, UK; 21 January 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, today announces its Interim Results for the six months ended 31 October 2020. I am pleased to report that Sensyne has made significant commercial progress over the past six months and has achieved several key milestones in the development of its research partnerships with NHS Trusts and in its work for leading pharmaceutical companies applying Clinical AI to improve patient care and accelerate life sciences research. I am particularly pleased with the results we have been able to achieve during the COVID-19 pandemic.
CMR Surgical appoints Catherine Moukheibir as Non-Executive Director
CMR Surgical appoints Catherine Moukheibir as Non-Executive Director
Cambridge, UK. 21 January 2021 (00:01 GMT). CMR Surgical (CMR), the Company behind the next-generation surgical robotic system Versius
, today announces the appointment of Catherine Moukheibir as Non-Executive Director.
Catherine is a highly respected healthcare executive with extensive experience in scaling and corporate governance. Catherine previously worked as a Chairman, Non-Executive Director and CEO in the biotech and pharmaceutical sector, successfully raising private and public capital as well as overseeing several major licencing deals and acquisitions over the last 20 years.
Catherine is currently a Non-Executive Director of a number of healthcare companies including Ironwood Pharmaceuticals Inc., Kymab Ltd and Orphazyme A/S. From this experience she will bring to CMR strong financial acumen and significant experience of chairing Au
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
NOVA awarded €2.4 million
to leverage Jinko®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease
1
2 -
to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab
ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease
Lyon, France – 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery (“NOVA”) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graf